Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 23, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of shareholding changes within a specific employee retirement plan and does not contain financial performance data.
Material Changes
The filing details movements in the GlaxoSmithKline US Retirement Savings Plan ("the Plan") on May 18 and May 19, 2006:
- May 18, 2006: Ordinary Share ADRs held by the fund decreased from 17,418,783 to 17,385,502 at an average price of $56.99.
- May 19, 2006: Ordinary Share ADRs held by the fund increased from 17,385,502 to 17,425,862 at an average price of $56.61.
These changes were notified to the company on May 22, 2006.
Management Commentary and Risks
The Plan is a discretionary fund where all employees or former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Two directors, Dr. J P Garnier and Dr. T Yamada, are noted as potentially interested in the shares held in the fund in the same manner as other employees. The notification complies with Disclosure Rule 3.1.4R(1)(b). No specific risks, contingencies, or unusual items regarding the company's operations are disclosed in this text.
Investor Verification Points
- Verify the total number of ADRs held by the US Retirement Savings Plan as of the latest reporting date (17,425,862).
- Confirm the average transaction prices ($56.99 and $56.61) against market data for May 18 and 19, 2006.
- Note that the reported transactions reflect fund movements rather than direct discretionary trading by the named directors.